Directorate Change

GlaxoSmithKline PLC
06 February 2006

Issued - Monday 6 February 2006, London



Dr Tachi Yamada to Retire; Dr Moncef Slaoui Appointed Successor as
 Chairman of R&D



GlaxoSmithKline plc (GSK) announces that Dr. Tadataka (Tachi) Yamada, 60,
Chairman, Research & Development and Executive Director, will retire on 1st June
2006 to take up the role of Executive Director, Global Health Program, for the
Bill & Melinda Gates Foundation. From that date, Dr. Moncef Slaoui, 46,
currently GSK's Senior Vice President, Worldwide Business Development and
External Alliances in R&D, will become Chairman, Research & Development,
reporting to Dr. Jean-Pierre Garnier, Chief Executive Officer. Dr. Slaoui will
join GSK's Board of Directors on 17th May 2006 and be put forward for election
as a Director at the company's AGM on that day.



Commenting on these changes, Dr. Garnier said: "Tachi has been a principal
architect behind the transformation and dramatic improvement in GSK's R&D
productivity, and he leaves GSK in a position of strength.  We now have an
impressive pipeline of innovative medicines that will benefit patients around
the world and provide a strong platform for GSK's future prosperity.



With his enormous experience and empathy for patients, Tachi will bring
inspirational leadership to the Gates Foundation in its global quest for better
healthcare. The Gates Foundation is a pivotal partner with GSK, and we look
forward to continuing a strong relationship with Tachi in his new role.



Moncef is a highly regarded scientist in industry and academia, and he has
played a key role in the development of GSK's strong pipeline of vaccines and
pharmaceutical medicines during his 17 years with the company.  His expertise in
new product development will enable him to lead GSK's R&D organisation into a
new era, as it delivers its exciting new pipeline."



Dr. Yamada said: "I am proud to have been part of GSK, a business that makes a
real difference to millions of patients all over the world. Our R&D organisation
is in excellent shape and I am confident that under Moncef's leadership, GSK
will continue to deliver many innovative medicines of significant value to
patients."



S M Bicknell

Company Secretary



6 February 2006




Enquiries:

UK Media enquiries:                      Philip Thomson          [phone]
                                         David Mawdsley          [phone]
                                         Chris Hunter-Ward       [phone]
                                         Alice Hunt              [phone]

US Media enquiries:                      Nancy Pekarek           [phone]
                                         Mary Anne Rhyne         [phone]
                                         Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries:     Duncan Learmouth        [phone]
                                         Anita Kidgell           [phone]
                                         Jen Hill                [phone]

US Analyst/ Investor enquiries:          Frank Murdolo           [phone]
                                         Tom Curry               [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange